| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Krzysztof Bednarz, Karolina Kowalczyk, Marlena Cwynar, Dominika Czapla, Wiktor Czarkowski, Dominika Kmita, Artur Nowak, Paweł Made. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International journal of molecular sciences. vol 23. issue 8. 2022-04-23. PMID:35457152. |
the role of glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. |
2022-04-23 |
2023-08-13 |
Not clear |
| Chinmay S Marathe, Hung Pham, Tongzhi Wu, Laurence G Trahair, Rachael S Rigda, Madeline D M Buttfield, Seva Hatzinikolas, Kylie Lange, Christopher K Rayner, Andrea Mari, Michael Horowitz, Karen L Jone. Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2022-04-23. PMID:35460043. |
acute administration of the glp-1 receptor agonist lixisenatide diminishes postprandial insulin secretion in healthy subjects but not in type 2 diabetes, associated with slowing of gastric emptying. |
2022-04-23 |
2023-08-13 |
human |
| Yusuke Seino, Yuji Yamazak. Roles of Glucose-Dependent Insulinotropic Polypeptide in Diet-Induced Obesity. Journal of diabetes investigation. 2022-04-22. PMID:35452190. |
a glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are incretins that play an important role in glucose metabolism, by increasing glucose-induced insulin secretion (giis) from pancreatic beta cells and help regulate body weight. |
2022-04-22 |
2023-08-13 |
Not clear |
| Kathleen L Wyne, Sheldon E Litwin, Kenneth Cusi, John R Guyto. JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. Journal of clinical lipidology. vol 16. issue 2. 2022-04-17. PMID:35430025. |
some medications approved for the treatment of type 2 diabetes may reduce liver fat (sglt2 inhibitors, insulin) or even reverse steatohepatitis in paired liver biopsy studies (glp-1 ras or pioglitazone) overall the field of preventive metabolic medicine is expanding. |
2022-04-17 |
2023-08-13 |
Not clear |
| Xuekun Wang, Guoxia Ji, Xinyu Han, Huiran Hao, Wenjing Liu, Qidi Xue, Qinghua Guo, Shiben Wang, Kang Lei, Yadi Li. Thiazolidinedione derivatives as novel GPR120 agonists for the treatment of type 2 diabetes. RSC advances. vol 12. issue 10. 2022-04-15. PMID:35424534. |
it is known that glp-1, as an incretin, can promote the insulin secretion from pancreatic cells in a glucose-dependent manner. |
2022-04-15 |
2023-08-13 |
mouse |
| Sonya Vasto, Francesca Di Gaudio, Maria Raso, Leo Sabatino, Rosalia Caldarella, Claudio De Pasquale, Luigi Di Rosa, Sara Baldassan. Impact on Glucose Homeostasis: Is Food Biofortified with Molybdenum a Workable Solution? A Two-Arm Study. Nutrients. vol 14. issue 7. 2022-04-12. PMID:35405964. |
blood was analyzed for glucose, insulin, insulin resistance, β-cell function, and insulin sensitivity, pyy, glp-1, glp-2 and gip. |
2022-04-12 |
2023-08-13 |
Not clear |
| Jasna Klen, Vita Dolža. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. International journal of molecular sciences. vol 23. issue 7. 2022-04-12. PMID:35408810. |
glucagon-like peptide-1 (glp-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. |
2022-04-12 |
2023-08-13 |
Not clear |
| Katherine M Roberts-Thomson, Lewan Parker, Andrew C Betik, Glenn D Wadley, Paul A Della Gatta, Thomas H Marwick, Michelle A Kesk. Oral and intravenous glucose administration elicit opposing microvascular blood flow responses in skeletal muscle of healthy people: role of incretins. The Journal of physiology. vol 600. issue 7. 2022-04-04. PMID:35045191. |
plasma insulin, c-peptide, glucagon, non-esterified fatty acids and a range of gut-derived hormones and incretins (gastric inhibitory polypeptide (gip) and glucagon-like peptide-1(glp-1)) were measured at baseline and throughout the ogtt/ivgtt. |
2022-04-04 |
2023-08-16 |
Not clear |
| Jorge F A Model, Débora S Rocha, Alessa da C Fagundes, Anapaula S Vinagr. Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals. Veterinary and animal science. vol 16. 2022-04-04. PMID:35372707. |
in diabetic dogs, the use of drugs based on glp-1 actions reduced blood glucose and increased glucose uptake, while in diabetic cats they reduced glycemic variability and exogenous insulin administration. |
2022-04-04 |
2023-08-13 |
human |
| Dihe Cheng, Shuo Yang, Xue Zhao, Guixia Wan. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug design, development and therapy. vol 16. 2022-03-28. PMID:35340338. |
glucagon-like peptide 1 receptor agonists (glp-1 ras) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. |
2022-03-28 |
2023-08-13 |
Not clear |
| Manal Ali Ahmad, Mirey Karavetian, Carole Ayoub Moubareck, Gabi Wazz, Tarek Mahdy, Koen Venem. The Association between Peptide Hormones with Obesity and Insulin Resistance Markers in Lean and Obese Individuals in the United Arab Emirates. Nutrients. vol 14. issue 6. 2022-03-26. PMID:35334929. |
we assessed their body mass index (bmi), waist circumference (wc), waist-to-height ratio (wthr), percentage body fat (pbf), fasting blood levels of peptide hormones (glp-1, glp-2, insulin, leptin, ghrelin, cck, and pyy), fasting blood sugar (fbs), and homeostatic model assessment of insulin resistance (homa-ir). |
2022-03-26 |
2023-08-13 |
human |
| Tejashree Redij, James A McKee, Phu Do, Jeffrey A Campbell, Jian Ma, Zhiyu Li, Nick Miller, Chananchida Srikanlaya, Dianzheng Zhang, Xianxin Hua, Zhijun L. 2-Aminothiophene Derivatives as a New Class of Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor. Chemical biology & drug design. 2022-03-21. PMID:35313084. |
insulin secretion studies found s-1 combined with glp-1 increased insulin secretion by 1.5-fold at 5 μm. |
2022-03-21 |
2023-08-13 |
Not clear |
| Linna Li, Anne-Marie Decker, Nicole Stobäus, Finja Beer, Ulrike Grittner, Joachim Spranger, Knut Ma. Weight loss did not modify macronutrient specific response of hormones and satiety in overweight and obese people without metabolic disease - results from a clinical trial. Clinical nutrition (Edinburgh, Scotland). vol 41. issue 4. 2022-03-18. PMID:35303516. |
we aimed to examine glp-1, gip, ghrelin, insulin, and satiety response to meals with different macronutrient composition in overweight and obese subjects before and after weight loss. |
2022-03-18 |
2023-08-13 |
human |
| Mateusz Wierdak, Edyta Korbut, Magdalena Hubalewska-Mazgaj, Marcin Surmiak, Katarzyna Magierowska, Dagmara Wójcik-Grzybek, Michał Pędziwiatr, Tomasz Brzozowski, Marcin Magierowsk. Impact of Vagotomy on Postoperative Weight Loss, Alimentary Intake, and Enterohormone Secretion After Bariatric Surgery in Experimental Translational Models. Obesity surgery. 2022-03-12. PMID:35277793. |
after 90 days, serum samples were collected to evaluate postprandial and fasting glp-1, gip, pyy, ghrelin, glucagon, insulin, leptin, and pancreatic polypeptide concentrations by fluorescent assay. |
2022-03-12 |
2023-08-13 |
rat |
| Carlos Bendicho-Lavilla, Iria Seoane-Viaño, Francisco J Otero-Espinar, Asteria Luzardo-Álvare. Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics. Acta pharmaceutica Sinica. B. vol 12. issue 2. 2022-03-08. PMID:35256935. |
the discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the identification of glucagon-like peptide-1 (glp-1) and the introduction of glp-1 receptor agonists (glp-1 ras) in clinical practice. |
2022-03-08 |
2023-08-13 |
Not clear |
| Junyuan Deng, Yujie Guo, Jiali Du, Jichun Gu, Lei Kong, Boan Tao, Ji Li, Deliang F. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. Frontiers in cell and developmental biology. vol 10. 2022-03-07. PMID:35252207. |
currently, taking glucose sensitizing agents, including metformin, sglt-2 inhibitor, and glp-1 agonist, is an effective way of lowering insulin levels and controlling pda development at the same time. |
2022-03-07 |
2023-08-13 |
Not clear |
| Eleonora Cremonini, Elena Daveri, Dario E Iglesias, Jiye Kang, Ziwei Wang, Russell Gray, Angela Mastaloudis, Colin D Kay, Shelly N Hester, Steven M Wood, Cesar G Fraga, Patricia I Oteiz. A randomized placebo-controlled cross-over study on the effects of anthocyanins on inflammatory and metabolic responses to a high-fat meal in healthy subjects. Redox biology. vol 51. 2022-03-07. PMID:35255426. |
the cdre did not significantly affect hfm-mediated increases in plasma insulin, glp-1, glp-2, gip, and ldl- and hdl-cholesterol, and ikk phosphorylation in pbmc. |
2022-03-07 |
2023-08-13 |
human |
| Harish C Chandramoorthy, Ayed A Dera, Ahmed Al-Hakami, Refaat A Eid, Ayyub Patel, Nouraldeen Mahmoud Faris, Anantharam Devaraj, Ashish Kumar, Mohammad Y Alshahrani, Gaffar S Zaman, Prasanna Rajagopala. Glucose and oleic acid mediate cellular alterations in GLP-1-induced insulin-positive differentiating UCBMSCs. Journal of food biochemistry. 2022-03-05. PMID:35246864. |
practical applications: the aim of this article was to study whether differentiating or differentiated mscs after mobilization or post-transplant would require optimal glucose and oleic acid to naturally stimulate intrinsic glp-1, or otherwise, the high or long-term overload of glucose or oleic acid could result in inhibition of differentiated cells resulting in failure of insulin secretion. |
2022-03-05 |
2023-08-13 |
Not clear |
| Kota Miyasak. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 157. issue 2. 2022-03-01. PMID:35228448. |
[new drug for type 2 diabetes: introduction of oral semaglutide (rybelsus glp-1 (glucagon-like peptide-1) is one of the incretin hormone secreted from l cells in the small intestine and it is known to promote insulin secretion in a glucose concentration-dependent manner and have a hypoglycemic effect. |
2022-03-01 |
2023-08-13 |
human |
| Kota Miyasak. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 157. issue 2. 2022-03-01. PMID:35228448. |
semaglutide is a glp-1 analog that has 94% homology with human glp-1 and it binds to the glp-1 receptor in pancreatic β-cells to induce the insulin secretion in a glucose concentration-dependent manner. |
2022-03-01 |
2023-08-13 |
human |